Susceptibility of the Aotus nancymaae owl monkey to eastern equine encephalitis

Benjamin J. Espinosa, Scott Weaver, Slobodan Paessler, Douglas Brining, Milagros Salazar, Tadeusz Kochel

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Eastern equine encephalitis virus (EEEV) is an arthropod-borne virus associated with life-threatening encephalitis in humans, equines, birds and many other domestic animals. To investigate the suitability of the Aotus nancymaae New World owl monkey as a viable animal model for EEE candidate vaccine testing we used clinical presentation, serology, viral isolation and PCR to evaluate pathogenesis and immunity in infected animals. Monkeys were inoculated subcutaneously (SQ) or intranasally (IN) with 104 pfu of virulent EEEV and were initially followed for 45 days. While none of the animals displayed clinical signs of disease, all of the SC inoculated animals (n = 6) manifested a viremia averaging 3.2 days (±0.8 days). Likewise, serologic responses (IgM, IgG and PRNT) were observed in all SC infected animals. Interestingly, none of the IN inoculated animals (n = 6) became viremic or mounted an antibody response and no pathological abnormalities were observed in two animals that were necropsied on day 6 post-infection (p.i.) from each group. To determine if the antibodies produced by the SC inoculated animals were protective against homologous challenge, three animals from the SC group were serologically evaluated on day 253 p.i. and were administered an inoculum identical to initial challenge on day 270 p.i. A positive control group of four naïve animals was also infected as before. All of the naïve positive control animals manifested a similar viremia as observed initially, averaging 2.75 days (±0.5 days) while none of the previously challenged animals became viremic. On days 45 and 253 p.i. geometric mean PRNT titers in the SC group were 453 and 101, respectively. This study demonstrates that the Aotus nancymaae can be reproducibly infected with EEE virus and can serve as a suitable model for infection and immunogenicity for the evaluation of candidate vaccines against EEEV.

Original languageEnglish (US)
Pages (from-to)1729-1734
Number of pages6
JournalVaccine
Volume27
Issue number11
DOIs
StatePublished - Mar 10 2009

Fingerprint

Eastern Equine Encephalomyelitis
Aotidae
Aotus (Cebidae)
encephalitis
horses
Eastern equine encephalitis virus
animals
Infection
infection
Viremia
viremia
Hemoglobin SC Disease
Vaccines
Platyrrhini
vaccines
Arboviruses
arboviruses
antibodies
Domestic Animals
Encephalitis

Keywords

  • Animal model
  • Aotus nancymaae
  • Eastern equine encephalitis (EEE)

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Susceptibility of the Aotus nancymaae owl monkey to eastern equine encephalitis. / Espinosa, Benjamin J.; Weaver, Scott; Paessler, Slobodan; Brining, Douglas; Salazar, Milagros; Kochel, Tadeusz.

In: Vaccine, Vol. 27, No. 11, 10.03.2009, p. 1729-1734.

Research output: Contribution to journalArticle

Espinosa, Benjamin J. ; Weaver, Scott ; Paessler, Slobodan ; Brining, Douglas ; Salazar, Milagros ; Kochel, Tadeusz. / Susceptibility of the Aotus nancymaae owl monkey to eastern equine encephalitis. In: Vaccine. 2009 ; Vol. 27, No. 11. pp. 1729-1734.
@article{8adce94e850345249d3ed07bf43e2ca0,
title = "Susceptibility of the Aotus nancymaae owl monkey to eastern equine encephalitis",
abstract = "Eastern equine encephalitis virus (EEEV) is an arthropod-borne virus associated with life-threatening encephalitis in humans, equines, birds and many other domestic animals. To investigate the suitability of the Aotus nancymaae New World owl monkey as a viable animal model for EEE candidate vaccine testing we used clinical presentation, serology, viral isolation and PCR to evaluate pathogenesis and immunity in infected animals. Monkeys were inoculated subcutaneously (SQ) or intranasally (IN) with 104 pfu of virulent EEEV and were initially followed for 45 days. While none of the animals displayed clinical signs of disease, all of the SC inoculated animals (n = 6) manifested a viremia averaging 3.2 days (±0.8 days). Likewise, serologic responses (IgM, IgG and PRNT) were observed in all SC infected animals. Interestingly, none of the IN inoculated animals (n = 6) became viremic or mounted an antibody response and no pathological abnormalities were observed in two animals that were necropsied on day 6 post-infection (p.i.) from each group. To determine if the antibodies produced by the SC inoculated animals were protective against homologous challenge, three animals from the SC group were serologically evaluated on day 253 p.i. and were administered an inoculum identical to initial challenge on day 270 p.i. A positive control group of four na{\"i}ve animals was also infected as before. All of the na{\"i}ve positive control animals manifested a similar viremia as observed initially, averaging 2.75 days (±0.5 days) while none of the previously challenged animals became viremic. On days 45 and 253 p.i. geometric mean PRNT titers in the SC group were 453 and 101, respectively. This study demonstrates that the Aotus nancymaae can be reproducibly infected with EEE virus and can serve as a suitable model for infection and immunogenicity for the evaluation of candidate vaccines against EEEV.",
keywords = "Animal model, Aotus nancymaae, Eastern equine encephalitis (EEE)",
author = "Espinosa, {Benjamin J.} and Scott Weaver and Slobodan Paessler and Douglas Brining and Milagros Salazar and Tadeusz Kochel",
year = "2009",
month = "3",
day = "10",
doi = "10.1016/j.vaccine.2009.01.029",
language = "English (US)",
volume = "27",
pages = "1729--1734",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "11",

}

TY - JOUR

T1 - Susceptibility of the Aotus nancymaae owl monkey to eastern equine encephalitis

AU - Espinosa, Benjamin J.

AU - Weaver, Scott

AU - Paessler, Slobodan

AU - Brining, Douglas

AU - Salazar, Milagros

AU - Kochel, Tadeusz

PY - 2009/3/10

Y1 - 2009/3/10

N2 - Eastern equine encephalitis virus (EEEV) is an arthropod-borne virus associated with life-threatening encephalitis in humans, equines, birds and many other domestic animals. To investigate the suitability of the Aotus nancymaae New World owl monkey as a viable animal model for EEE candidate vaccine testing we used clinical presentation, serology, viral isolation and PCR to evaluate pathogenesis and immunity in infected animals. Monkeys were inoculated subcutaneously (SQ) or intranasally (IN) with 104 pfu of virulent EEEV and were initially followed for 45 days. While none of the animals displayed clinical signs of disease, all of the SC inoculated animals (n = 6) manifested a viremia averaging 3.2 days (±0.8 days). Likewise, serologic responses (IgM, IgG and PRNT) were observed in all SC infected animals. Interestingly, none of the IN inoculated animals (n = 6) became viremic or mounted an antibody response and no pathological abnormalities were observed in two animals that were necropsied on day 6 post-infection (p.i.) from each group. To determine if the antibodies produced by the SC inoculated animals were protective against homologous challenge, three animals from the SC group were serologically evaluated on day 253 p.i. and were administered an inoculum identical to initial challenge on day 270 p.i. A positive control group of four naïve animals was also infected as before. All of the naïve positive control animals manifested a similar viremia as observed initially, averaging 2.75 days (±0.5 days) while none of the previously challenged animals became viremic. On days 45 and 253 p.i. geometric mean PRNT titers in the SC group were 453 and 101, respectively. This study demonstrates that the Aotus nancymaae can be reproducibly infected with EEE virus and can serve as a suitable model for infection and immunogenicity for the evaluation of candidate vaccines against EEEV.

AB - Eastern equine encephalitis virus (EEEV) is an arthropod-borne virus associated with life-threatening encephalitis in humans, equines, birds and many other domestic animals. To investigate the suitability of the Aotus nancymaae New World owl monkey as a viable animal model for EEE candidate vaccine testing we used clinical presentation, serology, viral isolation and PCR to evaluate pathogenesis and immunity in infected animals. Monkeys were inoculated subcutaneously (SQ) or intranasally (IN) with 104 pfu of virulent EEEV and were initially followed for 45 days. While none of the animals displayed clinical signs of disease, all of the SC inoculated animals (n = 6) manifested a viremia averaging 3.2 days (±0.8 days). Likewise, serologic responses (IgM, IgG and PRNT) were observed in all SC infected animals. Interestingly, none of the IN inoculated animals (n = 6) became viremic or mounted an antibody response and no pathological abnormalities were observed in two animals that were necropsied on day 6 post-infection (p.i.) from each group. To determine if the antibodies produced by the SC inoculated animals were protective against homologous challenge, three animals from the SC group were serologically evaluated on day 253 p.i. and were administered an inoculum identical to initial challenge on day 270 p.i. A positive control group of four naïve animals was also infected as before. All of the naïve positive control animals manifested a similar viremia as observed initially, averaging 2.75 days (±0.5 days) while none of the previously challenged animals became viremic. On days 45 and 253 p.i. geometric mean PRNT titers in the SC group were 453 and 101, respectively. This study demonstrates that the Aotus nancymaae can be reproducibly infected with EEE virus and can serve as a suitable model for infection and immunogenicity for the evaluation of candidate vaccines against EEEV.

KW - Animal model

KW - Aotus nancymaae

KW - Eastern equine encephalitis (EEE)

UR - http://www.scopus.com/inward/record.url?scp=60849105343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849105343&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.01.029

DO - 10.1016/j.vaccine.2009.01.029

M3 - Article

C2 - 19186197

AN - SCOPUS:60849105343

VL - 27

SP - 1729

EP - 1734

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 11

ER -